---
title: "Evercore ISI Sticks to Its Buy Rating for Revvity (RVTY)"
description: "Kumar covers the Healthcare sector, focusing on stocks such as Agilent, Edwards Lifesciences, and Exact Sciences. According to TipRanks, Kumar has an average return of 1.3% and a 49.45% success rate o"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/260149864.md"
published_at: "2025-10-07T10:45:54.000Z"
---

# Evercore ISI Sticks to Its Buy Rating for Revvity (RVTY)

> Kumar covers the Healthcare sector, focusing on stocks such as Agilent, Edwards Lifesciences, and Exact Sciences. According to TipRanks, Kumar has an average return of 1.3% and a 49.45% success rate on recommended stocks. Currently, the analyst consensus on Revvity is a Moderate Buy with an average price target of $110.46, representing a 18.29% upside. In a report released on October 2, Barclays also maintained a Buy rating on the stock with a $100.00 price target.

Kumar covers the Healthcare sector, focusing on stocks such as Agilent, Edwards Lifesciences, and Exact Sciences. According to TipRanks, Kumar has an average return of 1.3% and a 49.45% success rate on recommended stocks.

Currently, the analyst consensus on Revvity is a Moderate Buy with an average price target of $110.46, representing a 18.29% upside. In a report released on October 2, Barclays also maintained a Buy rating on the stock with a $100.00 price target.

### Related Stocks

- [RVTY.US - Revvity](https://longbridge.com/en/quote/RVTY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Revvity (RVTY) Receives a Buy from Bank of America Securities | According to TipRanks, Ryskin is a 4-star analyst with an average return of 4.3% and a 59.09% success rate. Ryskin cover | [Link](https://longbridge.com/en/news/263065353.md) |
| Revvity Inc. stellt neue High-Content-Screening- und Automationsplattformen für die Wirkstoffforschung vor | Revvity Inc. has announced the launch of several new platforms for scientific research at the SLAS2026 conference in Bos | [Link](https://longbridge.com/en/news/274977258.md) |
| Evercore ISI Sticks to Their Buy Rating for CVS Health (CVS) | Evercore ISI analyst Elizabeth Anderson maintained a Buy rating on CVS Health (CVS) with a price target of $100.00. Ande | [Link](https://longbridge.com/en/news/275622408.md) |
| Berenberg Bank Reaffirms Their Buy Rating on Novo Nordisk (0QIU) | Berenberg Bank analyst Kerry Holford has reaffirmed a Buy rating on Novo Nordisk (0QIU) with a price target of DKK360.00 | [Link](https://longbridge.com/en/news/275719942.md) |
| J.P. Morgan Reaffirms Their Buy Rating on Sartorius (0NIR) | J.P. Morgan analyst Richard Vosser has reaffirmed a Buy rating on Sartorius (0NIR) with a price target of €295.00. Vosse | [Link](https://longbridge.com/en/news/275586209.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
